BMY (bristol myers squibb) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BMY (bristol myers squibb)

BMY 42.82

-1.3%

Oct 28 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic

10/1/2018 6:10:30 PM

Read Replies (1) of 194

P109

Clinical efficacy of immune checkpoint inhibitors in patients with small cell lung cancer is associated with high tumor mutational burden and development of immune-related adverse events

Biagio Ricciuti1; Suzanne Dahlberg; Sasha Kravets2; Safiya Subegdjo; Renato Umeton; Adem Albayrak3; Lynette M. Sholl; Mark M. Awad

1University of Perugia - Dana Farber Cancer Institute; 2Dana Farber Cancer Institute; 3Dana-Farber Cancer Institute

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next